- Market Capitalization, $K 388,285
- Shares Outstanding, K 39,865
- Annual Sales, $ 960 K
- Annual Income, $ -155,650 K
- 60-Month Beta 2.36
- Price/Sales 414.93
- Price/Cash Flow N/A
- Price/Book 1.27
|Period||Period Low||Period High||Performance|
| || |
unch (unch)since 05/24/19
| || |
-2.81 (-22.85%)since 03/22/19
| || |
-6.18 (-39.44%)since 06/22/18
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the Jefferies Healthcare Conference...
We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...
Prothena's (PRTA) Q1 loss was narrower than expected, while revenues missed expectations.
Prothena (PRTA) delivered earnings and revenue surprises of 13.33% and -7.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to advance neuroscience pipeline...
- Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to advance neuroscience pipeline...
Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, will announce financial results for the first quarter of 2019 on May 7, 2019 after the close of the U.S. financial markets....
-- Results from final analysis of the composite primary endpoint were consistent with the futility analysis reported in April 2018
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Cleveland-Cliffs Inc. (NYSE:CLF),...